Biocon Limited opened a ₹4,150-crore qualified institutions placement on 12 January 2026. The floor price stands at ₹387.74 per share under SEBI ICDR norms. The issue follows board approval on 6 December 2025 and shareholder approval on 31 December 2025.
Source: Biocon Limited Press Release (NSE Exchange Filings) | Published on Jan 12, 2026
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release from Biocon Limited, the company has launched the qualified institutions placement with a target to raise, via the issuance of equity shares, up to ₹4,150 crore, following approval of the Board of Directors (December 2025) and of the shareholders through a special resolution at the extraordinary general meeting on 31 December 2025.
The issue has been opened on 12 January 2026 and the floor price for this issue is ₹387.74 per share, as defined by SEBI Issue of Capital and Disclosure Requirements Regulations. The placement has been completed as per the regulations pertaining to qualified institutional buyers and has been disclosed to the stock exchanges as part of the listing obligations.
The size of the QIP is set at ₹4,150 crore.
The price per equity share is ₹387.74.
The issue began on January 12, 2026.
The prices are set by the SEBI ICDR Regulations Board, and shareholder approvals were given in December 2025.
Biocon Limited, through the Fund Raising Committee, has announced that it will commence offering Qualified Institutional Placements on January 11th, 2006. The shares offered will be equity shares with a par value of Rs. 5/- each.
The total issue size has been fixed at ₹4,150 crore. The floor price of ₹387.74 per equity share has been calculated in line with Regulation 176 of the SEBI ICDR Regulations, 2018. The relevant date for determining the floor price has been set as 12 January 2026.
The company stated that the final issue price will be decided after the completion of the book-building process and in consultation with the book-running lead managers appointed for the issue.
At the board meeting on December 6th, 2025, there was a vote approving the fundraising. On December 31st, 2025, the shareholders at a special meeting also approved the funding by way of a special resolution.
The placement of shares will be pursuant to Chapter VI of the SEBI ICDR Regulations and the Companies Act, 2013, as well as any other applicable laws.
The disclosure has been filed with the stock exchanges under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
Biocon Limited stated that it may offer a discount of up to 5% on the floor price. This provision is subject to the shareholder approval already obtained at the extraordinary general meeting.
The final issue price will be determined based on the outcome of the placement process. No final pricing details were disclosed at the time of opening the issue.
Particulars | Details |
Issue Type | Qualified Institutions Placement |
Issue Size | ₹4,150 crore |
Face Value | ₹5 per equity share |
Floor Price | ₹387.74 per share |
Relevant Date | 12 January 2026 |
Approval Authority | Fund Raising Committee |
Biocon Limited share price closed lower on 12 January 2026. The stock ended the session at ₹370.90, registering a decline of 2.29% from the previous close.
During the session, the stock opened at ₹380.00 and touched an intraday high of ₹380.60. The day’s low stood at ₹365.95. The previous closing price was ₹379.60. The Biocon Limited share price movement was recorded at 15:30 PM IST on 12 January 2026.
Biocon Limited confirmed that the preliminary placement document has been filed with the stock exchanges following the opening of the qualified institutions placement. The disclosure was submitted for information and regulatory compliance and was signed by the Company Secretary and Compliance Officer in line with listing regulations.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading